A new study has said that estrogen, the female sex hormone, plays an important role in the development of 50 percent of all prostate cancers.
The researchers, led by Dr. Mark A. Rubin, professor of pathology and laboratory medicine, and vice chair for experimental pathology at Weill Cornell Medical College, also said that estrogen-linked signalling helps initiate a discrete and aggressive form of the disease caused by a chromosomal translocation, which in turn results in the fusion of two genes.
"Fifty percent of prostate cancers harbour a common recurrent gene fusion, and we believe that this confers a more aggressive nature to these tumours. Interfering with this gene fusion - or its downstream molecular pathways - will be crucial in the search for drugs that fight the disease. Based on our new data, we now believe that inhibiting estrogen may be one way of doing so," said Rubin.
Earlier, Rubin, along with researchers at the University of Michigan, discovered and described the common fusions between the TMPRSS2 and ETS family member genes subset of prostate cancer.
"The discovery showed that these malignancies occur after an androgen (male hormone)-dependent gene fuses with an oncogene - a type of gene that causes cancer," he explained.
While it has long been known that male hormones help spur prostate cancer and thus androgen-deprivation therapy is suggested as the first-line treatment against the disease. But still, the disease can progress despite androgen reduction, suggesting that other pathways might be at work.